Return to site


· MEDTECH,HEALTHCARE,diagnostics,INNOVATION,entrepreneurship
The House of MedTech provides a fast track acceleration and commercialization pathway for companies ready for scale, from the Asia Pacific to Europe to the US, through its bases in Singapore, Luxembourg and Silicon Valley. It makes a measurable contribution to transforming societies and healthcare worldwide.

SINGAPORE, December 18, 2020 ( -

General Partner Leesa Soulodre, launches House of MedTech in Luxembourg.

"Today it takes ~17 years to take a MedTech device from invention to clinical use," says R3i Ventures General Partner, Leesa Soulodre. With private health and life insurance costs on the rise globally and global shocks to supply chains, our pioneers are playing an active role in the digital transformation of healthcare, working closely with payers, industry and governments on personalised medicine, and the transition to value-based care."

The House of MedTech is built on Compass, an AI-based digital fabric, developed in collaboration with UCSF Health Hub, staged across Europe's research institutions. Designed over 18 months with guidance from the Luxembourg Ministry of Economy and LuxInnovation and inputs from a global network of industry stakeholders, Compass connects global healthcare visionaries with the talent, know-how, and access to capital and Incubation, to scale their breakthrough innovations for impact.


R3i is actively seeking export-ready companies with proven clinical studies in their home markets. Priority exporters are those with solutions that reduce the burden of hospitalization, over-hospitalization, or hospitalization; that improve patient outcomes and save lives, and that deliver efficiencies and transparency into the global healthcare value chain.

The Luxembourg Calling Program delivers a no equity, personalised, intensive three-month "land and expands" program, followed by a six-month in-market and capital focused incubation program. Founders are selected from domains of personalised diagnostics, digital health, medical devices, neurotech, digital therapeutics, and the future of food and agritech. Reimbursement is offered via Government export development programs.

R3i's network of Navigators includes seasoned international VCs, experts in healthcare and diagnostics innovation, IP, brand protection and anti-counterfeit, big data, cybersecurity, R&D, and artificial intelligence. Its MedTech Station provides an exclusive Singapore-based IVD partner to deliver a personalised medicine innovation pathway for those seeking access to Asian races.

The House of MedTech program aims to create 120 new jobs per year, contributing to the up-skilling and inclusivity of the labour workforce, and drive equal opportunities across R3i's Digital Health and MedTech ecosystems. An annual impact report will measure its societal and economic outcomes.

Naluri, Peach Intellihealth, Meracle Health, Prosoma, Orbit Health, SmartBeings Zinncare, and Stratificare were the first to test its programme's strength while in beta. Meracle Health was recently accepted into the healthcare incubation at Lux Fit 4 Start.

"We have forged a working relationship with the Luxembourg Institute of Health to validate Naluri as a digital therapeutics for chronic disease prevention. This firmly positions our company on the pathway for reimbursement and international scale," states President and Cofounder, Dr Jeremy Ting.

Dr Jeremy Ting, President & Cofounder of Naluri

"We’re incredibly excited to be part of the House of Medtech, as we sincerely believe that it will accelerate our mission to redefine tomorrow’s healthcare and tackle the global chronic disease epidemic.


By combining behavioural science, data science and digital design, Naluri is delivering a digital health platform that provides quantifiable health improvements in an affordable way, for non communicable disease prevention, in partnership with the world's largest insurers. Through the House of MedTech incubation program, we have been privileged and grateful to have forged a working relationship with an esteemed PI at the Luxembourg Institute of Health, to validate our digital solution in the context of diabetes prevention. This now puts us on a path to secure CE Mark regulatory approval, accelerate our access to non dilutive and smart capital, and firmly positions our European HQ for international scale.”

All Posts

Almost done…

We just sent you an email. Please click the link in the email to confirm your subscription!